Australia markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
17.01-0.11 (-0.64%)
At close: 04:00PM EDT
17.25 +0.24 (+1.41%)
After hours: 06:16PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 19.33B
Enterprise value 36.27B
Trailing P/E 872.00
Forward P/E 8.98
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.19
Price/book (mrq)2.65
Enterprise value/revenue 2.27
Enterprise value/EBITDA 27.46

Trading information

Stock price history

Beta (5Y monthly) 0.91
52-week change 3127.71%
S&P500 52-week change 325.69%
52-week high 317.69
52-week low 37.40
50-day moving average 315.41
200-day moving average 312.07

Share statistics

Avg vol (3-month) 39.84M
Avg vol (10-day) 38.42M
Shares outstanding 51.13B
Implied shares outstanding 61.14B
Float 81.13B
% held by insiders 10.00%
% held by institutions 151.92%
Shares short (15 May 2024) 412.22M
Short ratio (15 May 2024) 41.1
Short % of float (15 May 2024) 4N/A
Short % of shares outstanding (15 May 2024) 41.15%
Shares short (prior month 15 Apr 2024) 411.66M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 42.95
Payout ratio 40.00%
Dividend date 312 Dec 2017
Ex-dividend date 427 Nov 2017
Last split factor 22:1
Last split date 301 July 2004

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -2.99%
Operating margin (ttm)17.28%

Management effectiveness

Return on assets (ttm)4.84%
Return on equity (ttm)-9.67%

Income statement

Revenue (ttm)16B
Revenue per share (ttm)14.28
Quarterly revenue growth (yoy)4.30%
Gross profit (ttm)N/A
Net income avi to common (ttm)-478M
Diluted EPS (ttm)-0.42
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.99B
Total cash per share (mrq)2.64
Total debt (mrq)19.94B
Total debt/equity (mrq)264.33%
Current ratio (mrq)0.89
Book value per share (mrq)6.43

Cash flow statement

Operating cash flow (ttm)1.39B
Levered free cash flow (ttm)3.57B